Neurocrine Biosciences, Inc. (NBIX)

NASDAQ: NBIX · Real-Time Price · USD

154.06

-1.86 (-1.19%)

At close: Aug 28, 2026, 4:00 PM EDT

154.94

+0.88 (0.57%)

After-hours: Aug 28, 2026, 7:45 PM EDT

Neurocrine Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Capitalization	15,660	14,141	13,820	12,946	11,482	8,080
Market Cap Growth	14.31%	2.32%	6.75%	12.75%	42.11%	-9.78%
Enterprise Value	15,732	13,506	12,878	12,124	10,966	7,766
Last Close Price	154.06	141.83	136.50	131.76	119.44	85.17

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	22.58	29.55	40.49	51.85	74.32	90.18
Forward PE	13.80	15.87	18.15	21.34	22.53	24.55
PS Ratio	4.64	4.94	5.87	6.86	7.71	7.13
PB Ratio	4.24	4.35	5.34	5.80	6.72	5.88
P/TBV Ratio	16.19	4.35	5.34	5.91	6.90	5.88
P/FCF Ratio	17.99	18.89	24.80	35.80	35.56	34.66
P/OCF Ratio	17.44	18.07	23.21	33.20	33.83	31.50
PEG Ratio	0.34	0.75	0.31	0.65	0.66	1.12

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
EV/Sales Ratio	4.66	4.72	5.47	6.43	7.37	6.85
EV/EBITDA Ratio	17.23	20.26	20.64	29.14	41.44	35.51
EV/EBIT Ratio	18.17	21.22	21.57	30.71	44.04	37.38
EV/FCF Ratio	18.07	18.04	23.11	33.53	33.96	33.32

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Debt / Equity Ratio	0.13	0.14	0.18	0.19	0.15	0.32
Debt / EBITDA Ratio	0.47	0.65	0.68	0.99	0.94	1.88
Debt / FCF Ratio	0.53	0.63	0.82	1.19	0.81	1.89
Net Debt / Equity Ratio	0.02	-0.31	-0.24	-0.27	-0.42	-0.20
Net Debt / EBITDA Ratio	0.08	-1.51	-0.99	-1.45	-2.74	-1.24
Net Debt / FCF Ratio	0.08	-1.35	-1.11	-1.67	-2.25	-1.16
Asset Turnover	0.73	0.69	0.68	0.67	0.67	0.60
Inventory Turnover	14.88	16.90	15.99	16.48	14.85	11.71
Quick Ratio	1.46	2.92	3.06	2.25	2.49	3.65
Current Ratio	1.87	3.39	3.40	2.45	2.70	3.96
Return on Equity (ROE)	22.09%	16.38%	14.16%	12.68%	10.03%	7.17%
Return on Assets (ROA)	11.70%	9.53%	10.71%	8.78%	7.01%	6.82%
Return on Invested Capital (ROIC)	20.56%	20.50%	23.31%	22.75%	17.26%	19.95%
Return on Capital Employed (ROCE)	19.30%	16.40%	18.60%	15.20%	13.60%	11.40%

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Earnings Yield	4.51%	3.38%	2.47%	1.93%	1.35%	1.11%
FCF Yield	5.56%	5.29%	4.03%	2.79%	2.81%	2.89%
Buyback Yield / Dilution	-0.78%	1.16%	-2.67%	-2.12%	-1.02%	-0.10%

SEC Filings: 10-K · 10-Q